BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21478178)

  • 21. Management of Endometrial Hyperplasia: A Survey of Members of the Korean Gynecologic Oncology Group.
    Kim MK; Seong SJ; Kim JW; Bae DS; Jeon S; Kwon SH; Lee TS
    Int J Gynecol Cancer; 2015 Sep; 25(7):1277-84. PubMed ID: 26067858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
    van der Meer AC; Hanna LS
    Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
    Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
    Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
    Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a levonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome.
    Lin M; Xu X; Wang Y; Hu Y; Zhao Y
    Gynecol Obstet Invest; 2014; 78(1):41-4. PubMed ID: 24852134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
    Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
    Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levonorgestrel-releasing intrauterine device in the treatment of abnormal uterine bleeding: a 6- and 12-month morphological and clinical follow-up.
    Palmara V; Sturlese E; Villari D; Giacobbe V; Retto A; Santoro G
    Aust N Z J Obstet Gynaecol; 2013 Aug; 53(4):381-5. PubMed ID: 23701372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
    Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
    Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
    Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
    Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Dhont M
    Am J Obstet Gynecol; 2003 May; 188(5):1297-8. PubMed ID: 12748501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.